Kunlun Invests ￥30M in CuraCloud To Expand its AI-Powered Business

According to VCBeat, Beijing-based Kunlun Group Ltd. ("Kunlun") (stock code: 300418.SZ) announced that Kunnuo Tianqin, a wholly-owned subsidiary of the company, plans to invest ￥30 million in Curacloud Corp. ("Curacloud") and acquire 2.42% stake in Curacloud after its financing.

Beijing HuiGan Equity Investment LP., Guangzhou Hexie Kangjian Phase 2 Equity Investment LP. ("Hexie Kangjian"), Tibet Shulian Investment Co., Ltd. ("Tibet Shulian"), and other investors also participate in this financing. Among them, Hexie Kangjian and Tibet Shulian are subsidiaries of IDG capital.

CuraCloud is committed to collaboratively developing medical AI solutions with healthcare delivery organizations, medical technology leaders, and pharmaceutical companies to improve diagnostics, care processes, and clinical outcomes. Based on rich academic and industry experience in machine learning, medical image analysis, natural language processing, CuraCloud provides precise diagnosis and treatment services for patients, medical institutions and life science research institutions.

CuraCloud's "FFR (Fractional Flow Reserve) Calculated Software", taking more than three years to develop, has obtained the first registration certificate of the third class of medical devices in China as an AI-powered medical product, which is a milestone in the field of AI in healthcare in China.

Kunlun is an Internet group that is dedicated to the development of interactive platforms and applications for global user groups. The investment in CuraCloud is an important action for the company to invest in the field of IoT (Internet of things) and AI.

Around the "AI+" field, Kunlun has invested in Pony AI, Innoviz, Krazybee, and other AI technology companies in the past two years. According to a statement from Kunlun, the company is going to invest more in this field.